SUMMIT ONLINE SESSIONS SCHEDULE

Login and Registration
09:45  to  10:00
New European Guidelines affecting GCC
10:00  to  10:20
Speakers:
Dr. Mona Al Mouslli. Managing Director. PRA Group.
Mr Frank Dickert. Business Consultant. EXTEDO, Germany.
Q&A
10:20  to  10:30

Day 2 Session 3: Intellectual Property (IP) in Pharma

Day 2 Session 3: Intellectual Property (IP) in Pharma
How Intellectual Property (IP) in Pharma in GCC is different from Europe?
10:30  to  10:50
Speakers:
Mr. Jeffrey Kemprecos. Director, Communications, Government Affairs & Market Access--Gulf Countries. GSK, UAE.
Ms. Rim Ghedira. European Patent Attorney. Janssen Pharmaceutical, Belgium.
Day 2 Session 3: Intellectual Property (IP) in Pharma
Exclusion of Patency in Pharma & Market Authorization and Supplementary Protection Certificate
10:50  to  11:10
Speakers:
Mr. Jeffrey Kemprecos. Director, Communications, Government Affairs & Market Access--Gulf Countries. GSK, UAE.
Ms. Jinane Kabbara. Regional Cousellor for Intellectual Property Matters. Middle East Embassy of France in UAE.
Day 2 Session 3: Intellectual Property (IP) in Pharma
The Impact of Intellectual Property on Competitiveness in the Innovative Biopharmaceutical Sector in the Gulf Region
11:10  to  11:30
Speaker:
Mr. Jeffrey Kemprecos. Director, Communications, Government Affairs & Market Access--Gulf Countries. GSK, UAE.
Day 2 Session 3: Intellectual Property (IP) in Pharma
The GCC Patent regime for pharmaceutical inventions: Territorial scope and intersection with Drugs regulations
11:30  to  11:50
Speakers:
Mr. Jeffrey Kemprecos. Director, Communications, Government Affairs & Market Access--Gulf Countries. GSK, UAE.
Mr. Asif Iqbal. Head-IP Legal. Kadasa Intellectual Property. Saudi Arabia.
Day 2 Session 3: Intellectual Property (IP) in Pharma
Q&A
11:50  to  12:10
Coffee & Networking Break
12:10  to  12:30

Day 2 Session 3: Intellectual Property (IP) in Pharma
Discussion Session: The need for a high-standard, modern and unified IP system
12:35  to  13:15
Speakers:
Mr. Jeffrey Kemprecos. Director, Communications, Government Affairs & Market Access--Gulf Countries. GSK, UAE.
Ms. Rim Ghedira. European Patent Attorney. Janssen Pharmaceutical, Belgium.
Ms. Jinane Kabbara. Regional Cousellor for Intellectual Property Matters. Middle East Embassy of France in UAE.
Mr. Asif Iqbal. Head-IP Legal. Kadasa Intellectual Property. Saudi Arabia.
Lunch and Networking Break
13:15  to  14:30

Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt

Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
Regulatory Updates in Morocco
14:35  to  14:55

This session will throw light on the changing face of pharmaceutical regulation market in Morocco; the challenges faced in the pricesensitive market, the need to harmonize the regulatory framework, the opportunities for economic growth and the potential to become a destination for foreign investments.

Speakers:
Dr. Mona Al Mouslli. Managing Director. PRA Group.
Dr. Mohammed Wadie Zerhouni. Head of Pharmacy Division. Medicines and Pharmacy Directorate, Ministry of Health, Morocco.
Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
Overview of Regulations controlling Pharmaceutical products Registration in Egypt
14:55  to  15:15
Speakers:
Dr. Mona Al Mouslli. Managing Director. PRA Group.
Dr. Amal Mohamed Abdallah. Technical Director. Philo Pharm Pharmaceuticals, Egypt.
Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
Q&A
15:15  to  15:30
Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
The Evolving Pricing Regulations - Reflections on Saudi Arabia
15:30  to  15:50
Speakers:
Hatem Al Behairy. Regulatory Affairs Manager. Leo Pharma.
Dr Nadia Younis. Managing Partner. Stellar Pharma Consultancy MENA, UAE.
Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
Q&A
15:50  to  16:00
Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
The highest standards required to open and operate compounding pharmacy in GCC areas
16:00  to  16:20
Speakers:
Dr. Mona Al Mouslli. Managing Director. PRA Group.
Dr. Mohannad Salah. CEO/Owner. Fusion Apothecary, US.
Day 2 Session 4: The Regulations in Pharma in Morocco and Egypt
Q&A
16:20  to  16:30

Day 2 Session 5: - Emerging Regulatory Updates in the Pharma Market in GCC countries

Day 2 Session 5: - Emerging Regulatory Updates in the Pharma Market in GCC countries
Harmonization of regulatory policies, practices, standards, and legislation in Bahrain
16:30  to  16:50
Speakers:
Dr. Dina Fathy. Regulatory Affairs Director. Merck Sharp & Dohme -MSD, UAE.
Dr. Mariam Al Jalahma. CEO. National Health Regulatory Authority (NHRA), Bahrain.
Discussion Session: The effect of coordination, integration, and interconnection of regulations in GCC countries
16:50  to  17:20
Speakers:
Dr. Dina Fathy. Regulatory Affairs Director. Merck Sharp & Dohme -MSD, UAE.
Dr. Mariam Al Jalahma. CEO. National Health Regulatory Authority (NHRA), Bahrain.
Dr. Nisreen Mohammad Nassr. Senior Specialist Pharmacist. Ministry of Health, Oman.
Closing Remarks and Close of Summit
17:20  to  17:30
Speaker:
Dr. Mona Al Mouslli. Managing Director. PRA Group.